Equities Analysts Issue Forecasts for Kamada FY2024 Earnings

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright cut their FY2024 EPS estimates for Kamada in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.25 for the year, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.24 per share.

Separately, StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Stock Performance

NASDAQ KMDA opened at $5.91 on Monday. The firm has a 50 day simple moving average of $5.51 and a 200-day simple moving average of $5.47. Kamada has a one year low of $4.60 and a one year high of $6.53. The firm has a market cap of $339.71 million, a price-to-earnings ratio of 21.11 and a beta of 1.05.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada during the 3rd quarter worth approximately $77,000. Plato Investment Management Ltd purchased a new stake in shares of Kamada during the 3rd quarter worth approximately $117,000. Y.D. More Investments Ltd lifted its position in shares of Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after buying an additional 690,842 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after buying an additional 100,800 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.